Beacon Therapeutics

Executive Summary

Beacon Therapeutics is a clinical-stage gene therapy company dedicated to developing treatments for inherited retinal diseases (IRDs), with a primary focus on X-linked retinitis pigmentosa (XLRP). Founded in 2023 by Syncona, the company has rapidly advanced its lead asset, a novel AAV-based gene therapy designed to restore vision in patients with XLRP caused by RPGR mutations. Beacon has raised over $340 million to support its pipeline, reflecting strong investor confidence in its scientific approach and the large unmet need in IRDs. The company’s strategy combines robust preclinical data with a streamlined clinical development plan, aiming to become a leader in ophthalmic gene therapy. With a phase 2 trial ongoing, Beacon is positioned to generate pivotal efficacy and safety data that could support accelerated approval pathways. Its focused pipeline and experienced team underscore its potential to address significant vision loss in a genetically defined patient population.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim efficacy data readout for lead XLRP gene therapy65% success
• Q2 2027Initiation of pivotal Phase 3 trial design and regulatory alignment with FDA80% success
• TBDPotential partnership or licensing deal for non-lead pipeline assets50% success